A+ | A | A- | Skip to main content |

800 years stamp

Sensex

Nifty

USDINR

GBPINR

EURINR

BSE
NSE

Friday, 05 June 2026 12:00 AM EOD	Asian-Paints2685.15	Hind-Unilever2120.80	ITC280.75	Trent2774.65	Larsen-and-Toubro3953.95	M-and-M3040.75	Reliance-Industries1291.20	Tata-Steel206.80	Titan-Company4260.00	SBI977.75	Bharat-Electron408.05	Kotak-Mah-Bank377.50	Infosys1197.00	Bajaj-Finance889.15	Sun-PharmaInds1783.55	HDFC-Bank747.35	TCS2198.25	ICICI-Bank1262.20	Power-Grid-Corpn285.35	Maruti-Suzuki13048.60	Axis-Bank1273.15	HCL-Technologies1154.45	NTPC361.65	Bharti-Airtel1798.95	Tech-Mahindra1482.70	Adani-Ports1823.10	UltraTech-Cem10910.75	Bajaj-Finserv1703.10	Interglobe-Aviat4478.50	Eternal256.45
15 mins delay SENSEX 74,243.34 [-116.67]	23.45 0.88%	42.70 2.05%	0.45 0.16%	-62.65 -2.21%	14.45 0.37%	25.90 0.86%	-13.00 -1.00%	-3.75 -1.78%	33.05 0.78%	-1.90 -0.19%	-1.85 -0.45%	-3.85 -1.01%	-3.65 -0.30%	15.25 1.75%	4.20 0.24%	-7.20 -0.95%	-41.35 -1.85%	9.90 0.79%	0.70 0.25%	-9.50 -0.07%	20.75 1.66%	-14.05 -1.20%	-4.70 -1.28%	-19.40 -1.07%	-4.30 -0.29%	32.60 1.82%	-84.80 -0.77%	-6.85 -0.40%	-24.80 -0.55%	2.15 0.85%

Hot Pursuit

Scrips, which has significant changes during the market hours.

Zydus Lifesciences slips after Baddi units receives warning letter from US FDA

03-Jun-26 10:43Hrs IST

The warning letter was issued in response to a request for records pursuant to a section of the Federal Food, Drug, and Cosmetic Act, and does not pertain to any on-site inspection of the facility by the US FDA.

The communication references technical observations regarding the use of purified talc that did not meet the current United States Pharmacopeia (USP) requirements.

We believe that the said warning letter will not impact current operations and supplies from the Baddi site,' Zydus Lifesciences said in a statement.

The Baddi manufacturing facility was last subjected to an on-site inspection by the USFDA in August 2025.

Subsequent to the conclusion of the inspection, the company received the establishment inspection report (EIR) in October 2025, with the final compliance status classified as voluntary action indicated (VAI).

Zydus Lifesciences is an innovative, global lifesciences company that discovers, develops, manufactures, and markets a broad range of healthcare therapies.

The company's consolidated net profit jumped 8.68% to Rs 1,272.5 crore on 16.22% increase in revenue from operations to Rs 7,587 crore in Q4 FY26 over Q4 FY25.

Powered by Capital Market - Live News

Attention Investor :

"Prevent unauthorised transactions in your account ; Update your mobile numbers/email IDs with Us. Receive information of your transactions directly from Exchange on your mobile/email at the end of the day” - Issued in the interest of Investors"

"KYC is one time exercise while dealing in securities markets - once KYC is done through a SEBI registered intermediary (broker, DP, Mutual Fund etc.), you need not undergo the same process again when you approach another intermediary."

"No need to issue cheques by investors while subscribing to Equity IPO. Just write the bank account number and sign in the application form to authorise your bank to make payment in case of allotment. No worries for refund as the money remains in investor's account."

"Contents which are exclusively for Non-Broking Products/Services, "Mutual Fund, Mutual Fund-SIP, Research reports, Insurance, etc. where the Member is just a distributor. These are not Exchange traded product and the Member is just acting as distributor. It should also state that all disputes with respect to the distribution activity, would not have access to Exchange investor redressal forum or Arbitration mechanism."

A Muthoot M George Enterprise